Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
Lucid Diagnostics(LUCD) Prnewswire·2025-02-27 13:31Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a consortium of prestigious academic medical centers, led by principal investigators from Case Western Reserve University (CWRU) and University Hospit ...